FindTrial
Sign In

FHD-286

DRUG4 trials

Sponsors

Foghorn Therapeutics Inc., Montefiore Medical Center, Dana-Farber Cancer Institute

Conditions

Acute Myeloid LeukemiaAdvanced Hematologic MalignancyMetastatic Uveal MelanomaMyelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic SyndromesRelapsed Acute Myeloid Leukemia

Phase 1

FHD-286 in Subjects With Metastatic Uveal Melanoma
TerminatedNCT04879017
Foghorn Therapeutics Inc.Metastatic Uveal Melanoma
Start: 2021-05-11End: 2023-11-30Updated: 2024-04-25
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Active, not recruitingNCT04891757
Foghorn Therapeutics Inc.Advanced Hematologic Malignancy, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia +4
Start: 2021-06-14End: 2027-06-30Target: 144Updated: 2025-07-10
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RecruitingNCT07283094
Montefiore Medical CenterAcute Myeloid Leukemia, Myelodysplastic Syndrome
Start: 2026-02-03End: 2030-02-01Target: 33Updated: 2026-03-03

Phase 2

SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
Not yet recruitingNCT07551635
Dana-Farber Cancer InstituteSmall Cell Lung Cancer
Start: 2026-09-04End: 2029-01-31Target: 20Updated: 2026-04-27

Related Papers

Genomic and phenotypic impact of FHD-286–induced inhibition of SMARCA4/2 in patients with relapsed/refractory myeloid malignancies
Blood2025-11-03
Machine learning-powered integration of global proteomics and ex vivo sensitivity unveils a protein signature predictive of treatment success to AML therapy: Validation in patients treated with FHD-286, a SMARCA2/4 dual inhibitor
Blood2025-11-03
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Clinical Cancer Research2025-04-165 citations
Preclinical efficacy of BRG1/BRM ATPase inhibitor in B lymphoblastic leukemia.
Journal of Clinical Oncology2024-06-011 citations
Abstract A041: FHD-286, a potent and selective inhibitor of BRG1 and BRM, shifts metastatic uveal melanoma tumor towards a less immunosuppressive state in patient samples
Molecular Cancer Therapeutics2023-12-01
Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies
Blood2023-11-0220 citations
888 Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models
Regular and Young Investigator Award Abstracts2022-11-012 citations
Abstract LB190: Modulation of SPI1 transcriptional program contributes to the preclinical anti-tumor activity of SMARCA4/SMARCA2 ATPase inhibitors in AML
Cancer Research2022-06-15